Genetic toxicity assessment: employing the best science for human safety evaluation part IV: Recommendation of a working group of the Gesellschaft fuer Umwelt-Mutationsforschung (GUM) for a simple and straightforward approach to genotoxicity testing.
Based on new scientific developments and experience of the regulation of chemical compounds, a working group of the Gesellschaft fuer Umweltmutationsforschung (GUM), a German-speaking section of the European Environmental Mutagen Society, proposes a simple and straightforward approach to genotoxicity testing. This strategy is divided into basic testing (stage I) and follow-up testing (stage II). Stage I consists of a bacterial gene mutation test plus an in vitro micronucleus test, therewith covering all mutagenicity endpoints. Stage II testing is in general required only if relevant positive results occur in stage I testing and will usually be in vivo. However, an isolated positive bacterial gene mutation test in stage I can be followed up with a gene mutation assay in mammalian cells. If this assay turns out negative and there are no compound-specific reasons for concern, in vivo follow-up testing may not be required. In those cases where in vivo testing is indicated, a single study combining the analysis of micronuclei in bone marrow with the comet assay in appropriately selected tissues is suggested. Negative results for both end points in relevant tissues will generally provide sufficient evidence to conclude that the test compound is nongenotoxic in vivo. Compounds which were recognized as in vivo somatic cell mutagens/genotoxicants in this hazard identification step will need further testing. In the absence of additional data, such compounds will have to be assumed to be potential genotoxic carcinogens and potential germ cell mutagens.
Pfuhler
Stefan
S
P&G Prestige and Professional, Cosmital SA, Experimental Product Safety, Marly, Switzerland. pfuhler.s@pg.com
Albertini
Silvio
S
Fautz
Rolf
R
Herbold
Bernd
B
Madle
Stephan
S
Utesch
Dietmar
D
Poth
Albrecht
A
D000818:Animals; D001419:Bacteria / Q000187:drug effects / Q000235:genetics; D004353:Drug Evaluation, Preclinical; D006801:Humans; D015162:Micronucleus Tests; D009152:Mutagenicity Tests / Q000379:methods / Q000592:standards*; D009153:Mutagens / Q000633:toxicity*
D009153:Mutagens